(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 8.84%
@ $14.58
发出时间: 14 Feb 2024 @ 22:30
回报率: 5.38%
上一信号: Feb 13 - 03:52
上一信号:
回报率: 1.02 %
Live Chart Being Loaded With Signals
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors...
Stats | |
---|---|
今日成交量 | 447 000 |
平均成交量 | 494 825 |
市值 | 775.66M |
EPS | $0 ( 2024-03-14 ) |
下一个收益日期 | ( $-0.870 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.11 |
ATR14 | $0.0560 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Pons Jaume | Buy | 25 846 | Common Stock |
2024-04-16 | Pons Jaume | Sell | 50 000 | Common Stock |
2024-04-16 | Pons Jaume | Sell | 25 846 | Employee Stock Option (right to buy) |
2024-04-04 | Pons Jaume | Sell | 20 000 | Common Stock |
2024-03-14 | Lettmann Jason | Buy | 4 400 | Common Stock |
INSIDER POWER |
---|
87.31 |
Last 97 transactions |
Buy: 3 594 697 | Sell: 591 760 |
音量 相关性
ALX Oncology Holdings 相关性 - 货币/商品
ALX Oncology Holdings 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-836 000 (0.00 %) |
EPS: | $-3.74 |
FY | 2023 |
营收: | $0 |
毛利润: | $-836 000 (0.00 %) |
EPS: | $-3.74 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.47M (0.00 %) |
EPS: | $-3.03 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-4.52 |
Financial Reports:
No articles found.
ALX Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。